← Back to VTS Methodology
VTS Scoring Log — Archived

Strate Labs

stratelabs.is (formerly stratelabs.com) · Est. 2019 · Closed July 1, 2026 · Scored August 2026
⚑ Viability Flag Applied — Vendor No Longer Operating
Strate Labs closed operations on July 1, 2026, posting a sitewide closure notice before shutting down. The domain stratelabs.is now redirects to GL Peptides, an unrelated vendor with no connection to Strate Labs. This triggers PeptideClear's Viability Flag: storefront is defunct and the domain resolves to a different operator. The Viability Flag overrides the band regardless of underlying score. This entry is maintained as a historical archive. Do not use this vendor for supply planning.

Strate Labs operated from 2019 through June 2026 and used Janoshik Analytical for third-party testing with one of the broadest analytical suites documented in this catalog: NMR, FTIR, HPLC, LC-MS, GC-MS, TLC, ICP-MS, and additional methods. COAs were publicly accessible on product pages with verifiable Janoshik task IDs. The vendor was a named respondent in Eli Lilly's U.S. International Trade Commission tirzepatide complaint (filed March 2024), was found in default in May 2024, and was subject to a cease-and-desist order. The domain migrated from stratelabs.com to stratelabs.is concurrent with the ITC enforcement timing. Ownership was anonymous throughout its operation. The closure announcement cited a regulatory landscape that made continued operation untenable.

Historical Documentation Review (Informational Only)
DimensionMaxHistorical NotesHistorical Score
Third-Party Testing Practice 30 Janoshik Analytical (Prague) named as testing lab. Testing suite documented by the vendor's own FAQ: NMR, FTIR, HPLC, LC-MS, GC-MS, TLC, ICP-MS, Gravimetry, UV-Vis, Titration, Melting Point, Organoleptics. This is among the most comprehensive testing suites documented for any vendor in this catalog. Janoshik publishes results publicly with verifiable task IDs. Minor deduction for vendor-controlled publication model - vendors select which Janoshik results are made public. 28/30
Batch Traceability & Verification 20 Batch-coded COAs confirmed. Janoshik task IDs on COAs independently verifiable through Janoshik's public database without relying on vendor-hosted copies. Batch numbers appeared on vials and corresponded to COA entries. 16/20
COA Accessibility 15 COAs were publicly accessible on product pages without login during active operation. Janoshik task IDs provided independent verification path. 12/15
COA Completeness 15 Multi-method testing with HPLC, MS, NMR, and additional panels documented. Comprehensive scope exceeding most peers. Sterility and endotoxin testing confirmed for manufacturers. 13/15
Testing Recency 10 Actively publishing COAs through its operation period, with 2026 batch dates confirmed before closure. 8/10
Policy Transparency 5 Anonymous ownership throughout operation. Domain migration from .com to .is coincided with ITC enforcement timing. ITC default finding (May 2024) and cease-and-desist order on tirzepatide are documented public records. These are significant transparency gaps and legal posture signals. 1/5
Operational Track Record 5 Est. 2019, approximately 7 years of operation. Long track record offset by ITC enforcement action, anonymous ownership, and domain migration concurrent with legal proceedings. 2/5
Historical TotalViability Flag overrides band regardless of score. Archived entry only. 80/100
Scoring Notes
What the historical score reflects
The 80/100 historical score reflects a genuinely strong documentation model during active operation: a named lab, a comprehensive multi-method testing suite, and publicly accessible Janoshik-verified COAs with independent cross-verification paths. These are real signals that differentiated Strate Labs from less-documented peers. The historical score is preserved for archival accuracy.
ITC enforcement - a policy transparency gap that preceded closure
Strate Labs was a named respondent in Eli Lilly's ITC complaint targeting vendors of tirzepatide (Inv. No. 337). The vendor was found in default in May 2024 and was subject to a cease-and-desist order. The migration from stratelabs.com to stratelabs.is coincided with the timing of the ITC enforcement. Anonymous ownership made it impossible to verify the legal or corporate status of the operator. These are factual records from the ITC's public docket and are not characterizations of the vendor's testing quality.
Domain caution: stratelabs.is now resolves to a different vendor
The former stratelabs.is domain now redirects to GL Peptides, an unrelated vendor. Any researcher following a legacy link to stratelabs.is is reaching a different operator. PeptideClear does not score GL Peptides in this entry; they are a separate entity with no documented relationship to Strate Labs.
Sources: stratelabs.is FAQ (archived), ITC docket (Certain Tirzepatide and Products Containing Same, Inv. No. 337), published closure notices, Janoshik Analytical public COA database. Vendor closed July 1, 2026. Entry maintained as historical archive. PeptideClear has no affiliate, referral, or commercial relationship with Strate Labs. Last reviewed August 2026.